Literature DB >> 8662795

Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation.

U Hemmann1, C Gerhartz, B Heesel, J Sasse, G Kurapkat, J Grötzinger, A Wollmer, Z Zhong, J E Darnell, L Graeve, P C Heinrich, F Horn.   

Abstract

Distinct yet overlapping sets of STAT transcription factors are activated by different cytokines. One example is the differential activation of acute phase response factor (APRF, also called Stat3) and Stat1 by interleukin 6 and interferon-gamma. Interleukin 6 activates both factors while, at least in human cells, interferon-gamma recruits only Stat1. Stat1 activation by interferon-gamma is mediated through a cytosolic tyrosine motif, Y440, of the interferon-gamma receptor. In an accompanying paper (Gerhartz, C., Heesel, B., Sasse, J., Hemmann, U., Landgraf, C., Schneider-Mergener, J., Horn, F., Heinrich, P. C., and Graeve, L. (1996) J. Biol. Chem. 271, 12991-12998), we demonstrated that two tyrosine motifs within the cytoplasmic part of the interleukin 6 signal transducer gp130 specifically mediate APRF activation while two others can recruit both APRF and Stat1. By expressing a series of Stat1/APRF domain swap mutants in COS-7 cells, we now determined which domains of Stat1 and APRF are involved in the specific recognition of phosphotyrosine motifs. Our data demonstrate that the SH2 domain is the sole determinant of specific STAT factor recruitment. Furthermore, the SH2 domain of Stat1 is able to recognize two unrelated types of phosphotyrosine motifs, one represented by the interferon-gamma receptor Y440DKPH peptide, and the other by two gp130 YXPQ motifs. By molecular modeling, we propose three-dimensional model structures of the Stat1 and APRF SH2 domains which allow us to explain the different binding preferences of these factors and to predict amino acids crucial for specific peptide recognition.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662795     DOI: 10.1074/jbc.271.22.12999

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Cytoplasmic STAT proteins associate prior to activation.

Authors:  S Haan; M Kortylewski; I Behrmann; W Müller-Esterl; P C Heinrich; F Schaper
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

Review 2.  ALR and liver regeneration.

Authors:  Rafał Pawlowski; Jolanta Jura
Journal:  Mol Cell Biochem       Date:  2006-05-12       Impact factor: 3.396

Review 3.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

4.  A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation.

Authors:  D Besser; J F Bromberg; J E Darnell; H Hanafusa
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

5.  Internalization of the interleukin 6 signal transducer gp130 does not require activation of the Jak/STAT pathway.

Authors:  S Thiel; I Behrmann; E Dittrich; L Muys; J Tavernier; J Wijdenes; P C Heinrich; L Graeve
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

Review 6.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

7.  Signal transduction into the nucleus: fifth colloquium on cellular signal transduction. Heidelberg, Germany, January 1996.

Authors:  F Marks; P Angel
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

8.  Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells.

Authors:  Antje K Kretzschmar; Michaela C Dinger; Christian Henze; Katja Brocke-Heidrich; Friedemann Horn
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

Review 9.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

10.  LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.

Authors:  Li Pan; Xiang Chen; Shengling Fu; Wenying Yu; Chenglong Li; Tiffany Wang; Hui-Wen Lo; Jiayuh Lin
Journal:  Breast Cancer Res Treat       Date:  2020-04-02       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.